Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mDC3 Vaccine for Resected Hypermutated Colorectal Cancer
NCT03730948Phase 1Terminated
- Sponsor
- University of Pennsylvania
- Start
- Mar 2019
- Primary completion
- Feb 2022
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mDC3 vaccine in colorectal cancer (CRC), sponsored by University of Pennsylvania. Primary endpoints: Changes in Numbers of Peptide-specific CD8+ T Cells (Post-vaccine Immune Response) and Adverse Events Experienced by Subjects at 12 months. Started Mar 2019; status: terminated.
02
Drugs
mDC3 vaccine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03730948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03730948.